Neurocrine Biosciences In... (NBIX)

With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attracti...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with th...

Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.

Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity.

Biopharmaceutical giants Vertex Pharmaceuticals Inc  (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive O...

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stre...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago.